Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-180

AKKI: “that’s 1 lady having a hissy fit ……” AKKI you are honestly laughable…..now you are defending what can be considered a PER competitor. Anything is good for you to throw doubts on PER. In my opinion that hissy lady is talking on behalf of PPMD organisation so now what… are you going to say the PPMD are full of hissy parents?
As said before you are always always on the negative side in ref to PER. Do you have anything good to say about PER? Curious to know
quote
Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company’s recently approved gene therapy for Duchenne muscular dystrophy, STAT has learned.The incident raises questions about the financial ties between Sarepta and the dvocacy group, Parent Project Muscular Dystrophy, and whether the drugmaker uses its money to influence, or even muzzle, debate over its Duchenne medicines. It has also bolstered concerns voiced by some parents of young adults with Duchenne that Sarepta is more focused on profiting from its gene therapy, called Elevidys, than providing them with information necessary to prove its efficacy and safety, despite the blessing of the Food and Drug Administration
The video was recorded during a conference last month in Orlando sponsored By PP,D widely regarded as one of the largest and most influential Duchenne advocacy groups..
QUOTE